Industries > Pharma > Top 25 Dermatological Drugs Manufacturers 2019

Top 25 Dermatological Drugs Manufacturers 2019

Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies

PUBLISHED: 15 April 2019
PAGES: 176
PRODUCT CODE: PHA0380
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0380 Categories: , Tags: , , , , ,

Dermatological drugs market has been growing over the last decade. A combination of significant new market launches, and corporate activities has changed the outlook of the pharmaceutical industry towards this market. The dermatological drugs market in 2018 was reported to be US$ 26.23bn. Visiongain’s analysis of the market shows Humira, Stelara, Enbrel, Remicade, Otezla and Cosentyx among the top dermatological drugs driving the market at present.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 176-page report you will receive 108 tables and 71 figures– all unavailable elsewhere.

The 176-page report provides clear detailed insight into the top 25 dermatological drugs manufacturers. Discover the key drivers and challenges affecting the market.

Report Scope

• Assessment of the leading companies in the global dermatological drugs market. The list below shows some of the companies that are discussed in the report:
• Abbvie Inc.
• Allergan plc
• Almirall S.A.
• Amgen
• Astellas
• Bayer
• Concert Pharmaceuticals
• Eli Lilly and Company
• Galderma
• GlaxoSmithkline plc (GSK)
• Johnson & Johnson (J&J)
• Leo Pharma A/S
• Lupin Ltd
• Mayne Pharma
• Other companies

• For each company, the report provides information and discussion on:
• Total revenue forecast to 2028
• Dermatology segment revenue forecast to 2028
• The leading dermatology drugs revenue forecast to 2028
• Drugs portfolio
• Recent developments

• The report provides revenue forecast to 2028 for the following dermatological drugs:
• Epiduo
• Differin
• Stelara
• Remicade
• Humira
• Valtrex
• Lamisil
• Bactroban
• Dermovate
• Zyvox
• Protopic
• Solodyn
• Ziana
• Taltz
• Cosentyx
• Aczone
• Cubicin
• Elocon
• Absorica /Epirus
• Enbrel
• Doryx
• Canesten
• Bepanthen/Bepanthol

• Key questions answered by this report:
• How is the Dermatological Drugs Manufacturers market evolving?
• What is driving and restraining the Dermatological Drugs Manufacturers market?
• What will be the main driver for the overall market to 2028?
• Will leading Dermatological Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?

Visiongain’s study is intended for anyone requiring commercial analyses for the Top 25 Dermatological Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 25 Dermatological Drugs Manufacturers 2019: Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Top 25 Dermatological Drugs Manufacturers 2019


Download sample pages

Complete the form below to download your free sample pages for Top 25 Dermatological Drugs Manufacturers 2019


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category